Product information and disease descriptionProduct descriptionProduct informationPharmacology
Mechanism of action
5 evidence topics · 4 sources
Allosteric inhibition of TYK2 through the pseudokinase (JH2) domain
“In contrast, allosteric TYK2 inhibitors such as envudeucitinib achieve selectivity by binding to the pseudokinase JAK homology 2 (JH2) domain, a regulatory site unique to TYK2” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“This binding induces a conformational change that prevents the activation of the catalytic JH1 domain, thereby functionally blocking ATP binding and TYK2 signaling” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Because the TYK2 JH2 domain is structurally distinct from the JH2 domains of other JAK family members, this allosteric mechanism (indirect inhibition) confers high selectivity for TYK2, preserving JAK 1/2/3 activity and reducing the risk of adverse events associated with classic JAK inhibition” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“ESK‐001 is a highly selective allosteric inhibitor of tyrosine kinase 2 (TYK2), which plays an essential role in mediating cytokine signaling in multiple immune‐mediated diseases.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Here, we describe ESK‐001, an orally available and highly selective allosteric TYK2 inhibitor binding to the JH2 domain of TYK2, which is being developed for the treatment of plaque psoriasis, SLE, and other immune‐mediated diseases.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Cytokine pathways mediated by TYK2
“TYK2 mediates downstream signaling of IL-23 as well as other cytokines, including IL-12 and type I interferons (IFNs)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Thus, inhibition of TYK2 provides comprehensive targeting that reduces both the signaling and production of the proinflammatory cytokines central to psoriasis pathogenesis.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Inhibition of TYK2 reduces production and inflammatory signaling of cytokines associated with psoriasis without affecting cytokines involved in immune pathways, lipid metabolism, and blood cell development.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Selectivity for TYK2 over JAK1, JAK2, and JAK3
“Preclinical studies showed that ESK‐001 was pharmacologically active and highly selective against TYK2 (50% inhibitory concentration [IC50] of 104–149 nM in human whole blood), and had no off‐target effects on other kinases (IC50 of >30,000 nM for JAK1‐3).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote